Amgen and biopharmaceutical company Medicines Development for Global Health have entered into a license agreement for Amgen's AMG 634 drug for the treatment of tuberculosis and leprosy nodular erythema, an inflammatory cutaneous and systemic complication of leprosy. Under the terms of the agreement, MDGH will assume full responsibility for the further development and commercialization of AMG 634. The drug is currently in Phase II clinical trials.